C4 Therapeutics (CCCC) Operating Leases (2019 - 2026)
C4 Therapeutics (CCCC) posted quarterly Operating Leases of $51.9 million for Q1 2026, down 11.16% year-over-year from $58.4 million in Q1 2025, and down 3.15% quarter-over-quarter from $53.6 million in Q4 2025.
C4 Therapeutics (CCCC) Operating Leases (2019 - 2026) Analysis & Trends
C4 Therapeutics' Operating Leases history runs 8 years deep, the most recent figure standing at $51.9 million for Q1 2026.
- In Q1 2026, Operating Leases fell 11.16% year-over-year to $51.9 million; the TTM figure through Mar 2026 stood at $51.9 million (down 11.16% YoY), while the FY2025 annual figure was $53.6 million, down 10.61% from the prior year.
- Operating Leases for Q1 2026 stood at $51.9 million, down from $53.6 million in the prior quarter.
- The five-year high for Operating Leases was $75.2 million in Q2 2022, with the low at $51.9 million in Q1 2026.
- The 5-year median for Operating Leases is $64.4 million (2024), against an average of $64.1 million.
- The sharpest annual moves came in 2022 and 2026: Operating Leases surged 569.59% in 2022, then declined 11.16% in 2026.
- C4 Therapeutics' Operating Leases stood at $71.0 million in 2022, then declined by 7.35% to $65.8 million in 2023, then declined by 8.78% to $60.0 million in 2024, then decreased by 10.61% to $53.6 million in 2025, then declined by 3.15% to $51.9 million in 2026.
- Business Quant data shows CCCC's Operating Leases at $51.9 million in Q1 2026, $53.6 million in Q4 2025, and $55.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | C4 Therapeutics | 521.12 Mn | 267.46 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 50.18 Mn |
| Mar 31, 2026 | 51.93 Mn |
| Dec 31, 2025 | 53.62 Mn |
| Sep 30, 2025 | 55.25 Mn |
| Jun 30, 2025 | 56.86 Mn |
| Mar 31, 2025 | 58.45 Mn |
| Dec 31, 2024 | 59.98 Mn |
| Sep 30, 2024 | 61.46 Mn |
| Jun 30, 2024 | 62.92 Mn |
| Mar 31, 2024 | 64.37 Mn |
| Dec 31, 2023 | 65.76 Mn |
| Sep 30, 2023 | 67.10 Mn |
| Jun 30, 2023 | 68.42 Mn |
| Mar 31, 2023 | 69.72 Mn |
| Dec 31, 2022 | 70.97 Mn |
| Sep 30, 2022 | 72.18 Mn |
| Jun 30, 2022 | 75.20 Mn |
| Mar 31, 2022 | 74.75 Mn |
| Dec 31, 2021 | 30.78 Mn |
| Sep 30, 2021 | 10.92 Mn |